Pre-surgery chemotherapy plus treatment for stomach lining spread
Part of Cancer, Digestive system clinical trials.
This trial studies chemotherapy given before surgery for advanced stomach (gastric) cancer, including treatment when cancer may be on the stomach lining (peritoneum). It may help shrink tumors and improve outcomes for people who meet specific marker and staging requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach adenocarcinoma with lymph nodes involved in an expected way (T1–3, N1–3).
- Your tests show either cancer cells in stomach-lining fluid (cytology positive) or a low cancer spread score (PCI 3 or less).
- You do not have spread to solid organs (like liver or lungs).
- Your tumor is HER2-negative (not the HER2-positive type).
- You have not had cancer treatment before (treatment-naïve).
- Your general health and symptoms are limited: performance status 0–1, dysphagia score 0–2, BMI 18.5–40, and blood counts are sufficient (hemoglobin at least 90 unless corrected).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs given before surgery for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
This study tests whether a thorough surgery to remove stomach cancer in the abdomen, followed by chemotherapy given through the belly and by vein, can improve outcomes. It’s for people newly diagnosed with stomach cancer that has limited spread to the belly lining.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of a special chemotherapy sprayed into the abdomen (PIPAC) and a minimally invasive surgery to remove the stomach in people with high-risk stomach cancer. The goal is to see if this approach can improve outcomes for patients whose cancer has grown into the stomach wall or spread to abdominal fluid but not to other organs.
This trial tests a combination of immunotherapy and chemotherapy given before surgery to shrink stomach cancers that are particularly thick or large. It aims to see if this approach can make these hard-to-treat tumors easier to remove and improve outcomes.
This trial tests a combination of chemotherapy (DOS) plus an immunotherapy drug (Adebrelimab) given before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if the treatment shrinks the tumor and improves outcomes.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.